Autobio Diagnostics Co Ltd
SSE:603658
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
38.18
66.36
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Autobio Diagnostics Co Ltd
Autobio Diagnostics Co Ltd
Accounts Receivables
Autobio Diagnostics Co Ltd
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Autobio Diagnostics Co Ltd
SSE:603658
|
Accounts Receivables
¥1.2B
|
CAGR 3-Years
10%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
Shandong Weigao Group Medical Polymer Co Ltd
HKEX:1066
|
Accounts Receivables
¥6.3B
|
CAGR 3-Years
9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
Eyebright Medical Technology Beijing Co Ltd
SSE:688050
|
Accounts Receivables
¥212.8m
|
CAGR 3-Years
42%
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
|
|
Winner Medical Co Ltd
SZSE:300888
|
Accounts Receivables
¥768.6m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
Accounts Receivables
¥620.5m
|
CAGR 3-Years
42%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
Intco Medical Technology Co Ltd
SZSE:300677
|
Accounts Receivables
¥1.3B
|
CAGR 3-Years
18%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
Autobio Diagnostics Co Ltd
Glance View
Autobio Diagnostics Co., Ltd. engages in the research, development, manufacturing, integration, service, and distribution of in vitro diagnostic reagents and instruments. The company is headquartered in Zhengzhou, Henan and currently employs 5,031 full-time employees. The company went IPO on 2016-09-01. The firm's main products include gnostic products, microbiology detection products, and related devices. The immunodiagnostic products include microplate chemiluminescence diagnostic reagents, Enzyme-Linked immunosorbent assay diagnostic reagents, magnetic particle chemiluminescence detection reagents, and colloidal diagnostic reagents. The microbiology detection products include training detection reagents, susceptibility detection reagents and rapid detection reagents. The device products include microplate readers, chemiluminescence immunoassay analyzers, and united testing analyzers. The firm distributes its products in domestic markets.
See Also
What is Autobio Diagnostics Co Ltd's Accounts Receivables?
Accounts Receivables
1.2B
CNY
Based on the financial report for Jun 30, 2024, Autobio Diagnostics Co Ltd's Accounts Receivables amounts to 1.2B CNY.
What is Autobio Diagnostics Co Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
22%
Over the last year, the Accounts Receivables growth was 15%. The average annual Accounts Receivables growth rates for Autobio Diagnostics Co Ltd have been 10% over the past three years , 22% over the past five years .
You don't have any saved screeners yet
